Trevena Announces Publication of OLINVYK Health Economic Model in Journal of Comparative Effectiveness Research
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of
Trevena Announces Initiation of OLINVYK Respiratory Physiology Study Including Elderly / Obese Subjects
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has initiated a
Trevena Announces NIH Has Resumed Recruiting Patients In Proof-Of-Concept Study For TRV734 In Opioid Use Disorder
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that NIDA has resumed
Trevena’s TRV027 Included In Global COVID-19 Study
Trevena Inc (NASDAQ: TRVN) has announced that its novel AT1 receptor-selective agonist, TRV027, has been selected for inclusion in an international Phase…